Currency In USD
| Previous Close | 3.18 |
| Open | 3.18 |
| Day High | 3.18 |
| Day Low | 3.18 |
| 52-Week High | 4.18 |
| 52-Week Low | 1.13 |
| Volume | 0 |
| Average Volume | 14.97M |
| Market Cap | 661.15M |
| PE | -53 |
| EPS | -0.06 |
| Moving Average 50 Days | 3.15 |
| Moving Average 200 Days | 3.09 |
| Change | 0 |
Data not available
Esperion Therapeutics and Corstasis Therapeutics Announce Esperion’s Definitive Agreement to Acquire Corstasis, Expanding Its Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray)
GlobeNewswire Inc.
Mar 03, 2026 11:00 AM GMT
– Enbumyst™ Is the First and Only FDA-Approved Nasal Spray Loop Diuretic for Edema Associated with Congestive Heart Failure, Expected to Leverage Esperion’s Established Cardiovascular Commercial Infrastructure, Synergistically Expand Product Portfoli
Esperion to Report Fourth Quarter and Full Year 2025 Financial Results on March 10
GlobeNewswire Inc.
Feb 24, 2026 1:00 PM GMT
ANN ARBOR, Mich., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it will report fourth quarter and full year 2025 financial results before the market opens on Tuesday, March 10, 2026. Following the release, management wil
Esperion to Participate in The 2026 Citizens Life Sciences Conference
GlobeNewswire Inc.
Feb 18, 2026 1:00 PM GMT
ANN ARBOR, Mich., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will be participating in the webcasted 2026 Citizens Life Sciences Conference on March 11, 2026, at 8:25 a.m. ET. The live webcast can be a